Pfizer Inc. - PFE STOCK NEWS

Astellas Pharma will present 13 abstracts at the 2022 ASCO Annual Meeting and EHA 2022 Hybrid Congress, focusing on advanced and rare cancers, including prostate and pancreatic cancers. Highlights include findings from Phase 3 and 2 trials for therapies like enfortumab vedotin and zolbetuximab. Presentations aim to enhance treatment strategies for metastatic cancers. Astellas emphasizes its commitment to advancing oncology through innovative research and strategic collaborations, particularly with Pfizer on enzalutamide.

Pfizer has announced its acquisition of Biohaven, the maker of NURTEC® ODT, for approximately $11.6 billion. Shareholders will receive $148.50 per share in cash and shares in a new company retaining Biohaven's non-CGRP assets. The acquisition enhances Pfizer's Internal Medicine pipeline, focusing on migraine treatments with high market potential. NURTEC is already the leading migraine therapy in the U.S. The deal includes the purchase of Biohaven's CGRP programs and is expected to close by early 2023, pending approvals.

Pfizer (PFE) reported strong Q1 2022 revenues of $25.7 billion, marking an 82% operational growth. Excluding COVID-related revenues from Comirnaty and Paxlovid, operational growth was 2%. Reported diluted EPS was $1.37, with an adjusted EPS of $1.62. Despite challenges from foreign exchange impacts, Pfizer reaffirms its full-year revenue guidance of $98-102 billion and adjusted EPS of $6.25-6.45. The company has also begun share repurchases, totaling $2 billion in Q1. Key developments include continued success in vaccine distribution and ongoing clinical trials.

MOBItalks returns to New York on May 14, 2022, focusing on alternative wellness and community empowerment for Black gay men. Presented by ViiV Healthcare and the Mobilizing Our Brothers Initiative (MOBI), the event features speakers and provides networking opportunities. Attendees can enjoy free professional headshots and brunch by Cornbread26 Food Co. MOBI, active since 2017, aims to enhance personal development and community wellness, having contributed over $1 million to the Black queer community. For registration, visit mobi-nyc.com/nyctalks.

Pfizer Inc. (NYSE: PFE) has declared a quarterly cash dividend of $0.40 per share, scheduled for payment on June 10, 2022. This dividend will benefit shareholders of record by May 13, 2022. Notably, this marks the 334th consecutive dividend payment by Pfizer, showcasing the company's commitment to returning value to its investors.

Pfizer (NYSE: PFE) and Biohaven (NYSE: BHVN) announced the European Commission's marketing authorization for VYDURA® (rimegepant), the first medication approved for both acute and prophylactic treatment of migraines in adults. VYDURA® is an orally disintegrating tablet that targets a significant unmet need for migraine treatment in the EU, affecting around one in ten people. Clinical studies demonstrate its efficacy in reducing migraine symptoms and the frequency of attacks. The approval covers all 27 EU countries, with local reimbursement to follow.

Valneva SE and Pfizer reported positive Phase 2 results for their Lyme disease vaccine candidate, VLA15, showing a strong immunogenic response in participants aged 5-17. One month post-vaccination, pediatric participants demonstrated better immunogenicity compared to adults. The safety profile was consistent with earlier adult trials, with no serious adverse events noted. Both companies plan to include pediatric participants in the upcoming Phase 3 trial, set to begin in Q3 2022, pending regulatory approval.

Pfizer Inc. (NYSE: PFE) will hold its 2022 Annual Meeting of Shareholders virtually on April 28, 2022, starting at 9:00 a.m. EDT. Shareholders should log in at 8:45 a.m. EDT using their control numbers to participate fully. Questions can be submitted in advance until 5:00 p.m. EDT on April 26. Guests can listen without a control number. The webcast will be accessible for one year post-meeting. Shareholders can find registration details at www.meetnow.global/MWPVZT2.

Pfizer and BioNTech announced positive results from their Phase 2/3 clinical trial, showing a 36-fold increase in SARS-CoV-2 Omicron neutralizing titers after a booster dose for children aged 5-11. The booster also resulted in a 6-fold increase against the wild-type strain. In total, the trial involved 140 children, with no new safety signals reported. The companies plan to submit data for Emergency Use Authorization (EUA) in the U.S. soon, along with submissions to other global regulatory agencies.